ARNMUNE. Development of mRNA-based cancer immunotherapy.
The treatment of people with cancer has progressed at a dizzying pace due to advances in cancer immunotherapy. However, not all of these people respond, and identifying those sensitive to immunotherapy treatments and developing new, more rapid, cost-effective translational strategies are needed.
The ARNMUNE project proposes to develop clinical trials based on preclinical research on mRNA drugs. In Navarra, we have experts in immunotherapy with international prestige in basic and preclinical research and clinical development (clinical trials). In addition, we have well-established pharmaceutical companies as leaders in stimulating the immune system against cancer and developing advanced drugs based on galenic innovations.
The ARNMUNE project arises to unite and consolidate the synergic collaboration between these groups to promote immunotherapy treatments exploiting mRNA technology, to validate new treatments in experimental models optimizing the use of infrastructures, and to promote the participation and performance of clinical trials of cancer immunotherapy in hospitals in Navarra.
- Convocation: FIMA 2023 GN STRATEGIC R&D PROJECTS 2023-2026
- Reference: 0011-1411-2023-000032
- Start date: September 1, 2023
- End date: December 31, 2025
- Funder: Gobierno de Navarra
- Nature of project: Regional
- Award year 2023